MHLW Approves Lilly’s Migrane Drug Reyvow, Amgen’s KRAS Inhibitor and More

January 21, 2022
Japan’s Ministry of Health, Labor and Welfare (MHLW) on January 20 approved a batch of new medicines including Eli Lilly’s Reyvow (lasmiditan succinate), a treatment for migraines, and Amgen’s KRAS G12C inhibitor Lumakras (sotorasib) for lung cancer. Reyvow is a...read more